Dinaciclib in Treating Patients With Stage IV Melanoma

Brief summary (registry, in English)

This phase II trial is studying the side effects and how well dinaciclib works in treating patients with stage IV melanoma. Dinaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

What you commit to

• Study type: Interventional · Phase 2
• Participants enrolled: 72
• From Jul 2009 to the primary completion date, Oct 2013
• 190 sites in 1 country
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Who the study is looking for

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (190)

Sites in registry order. Pick your city on the disease page to sort them by distance.